How Retatrutide Works (Mechanism of Action) In biochemical and preclinical research models, retatrutide interacts with three class B G protein coupled receptors that participate in metabolic signaling networks: the glucagon like peptide 1 receptor (GLP 1R), the glucose dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)

p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis

Microbiota changes induced by GLP-1RA treatment initiate two interlinked effects
Im lactose intolerant, and I dont do very well with most dairies either
Which One the Research Question Calls For The choice between BPC-157 and TB-500 is rarely a matter of which is better it is a matter of which mechanism aligns with the research question